Boundless Bio Amends Serapha Bio Merger Terms: Adds RSU Conversion, Pre-Funded Warrants, and Lower Voting Threshold
BOLD has more than doubled off its 52-week low of $0.961 on light trading volume (0.1× avg).
Summary
Boundless Bio amended its pending reverse merger agreement with Serapha Bio, adding RSU conversion mechanics, pre-funded warrants for holders exceeding ownership limits, and a lower voting threshold for the authorized share increase.
Key Events · M&A and Partnerships · BOLD
-
Merger Agreement Amended
Amendment No. 1 to the June 22, 2026 merger agreement with Serapha Bio adds RSU conversion mechanics, pre-funded warrants, and a lower voting threshold for the authorized share increase.
-
Serapha RSU Conversion Mechanics
Each outstanding Serapha RSU (vested or unvested) converts into an Assumed RSU covering Boundless Bio common stock, with share count adjusted by the Exchange Ratio.
-
Pre-Funded Warrants Introduced
Holders exceeding their Beneficial Ownership Limitation will receive pre-funded warrants (exercise price $0.00001 per share) in lieu of excess Boundless Bio shares, preserving economic effect.
-
Voting Threshold Lowered
The authorized share increase now requires a majority of shares properly cast rather than a majority of shares outstanding and entitled to vote, reducing the hurdle for approval.
Analysis · BOLD · Life Sciences
Boundless Bio and Serapha Bio signed Amendment No. 1 to their June 22, 2026 merger agreement, introducing several material changes. The amendment adds mechanics for converting Serapha restricted stock units into Boundless Bio RSUs, creates pre-funded warrants (exercise price $0.00001) to be issued as merger consideration when share issuance would breach beneficial ownership limits, and lowers the voting threshold for the authorized share increase from a majority of outstanding shares to a majority of shares properly cast. These changes reduce friction to closing the reverse merger and provide flexibility for large Serapha holders to receive consideration without triggering ownership caps. The amendment also clarifies the pre-closing financing condition, requiring at least the minimum gross cash proceeds to be received. Against the backdrop of Boundless Bio's halted R&D, 75% staff reduction, and $72.6M in remaining cash, this amendment signals continued progress toward completing the transformative reverse merger with Serapha Bio.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLD was trading at $2.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.4M. The 52-week trading range was $0.96 to $3.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.